Caidya vs Regeneron
Side-by-side comparison of AI visibility scores, market position, and capabilities
Caidya is a global mid-sized CRO formed from the merger of dMed Global and Clinipace; operates in 20+ countries across 50+ regions; raised $165M from Rubicon Founders in January 2025;
About
Caidya is a global, full-service contract research organization (CRO) formed in 2021 through the merger of dMed Global, a Shanghai-based clinical research firm, and Clinipace Incorporated, a North Carolina-based CRO. The combined entity rebranded as Caidya with a mission to "liberate clinical research" by providing more personalized, knowledge-driven CRO services to biopharmaceutical innovators developing breakthrough therapies for patients with unmet medical needs. Headquartered in Raleigh, North Carolina, Caidya operates across more than 20 countries with study execution capabilities spanning more than 50 countries and regions — including deep expertise in the Americas, Europe, and Asia-Pacific, particularly Mainland China.
Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.
About
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.